Dry eyedisease compounds…
177
72.
Dor JP, Nivaggioli T, Reilly P, et al. mTOR pathway inhibitors for treating
ocular disorders.WO2010129622 (2010)
73.
CaoGF, LiuY, YangW, et al. Rapamycin sensitivemTOR activationmediates
nerve growth factor (NGF) induced cell migration and pro-survival effects against
hydrogen peroxide in retinal pigment epithelial cells.
Biochem Biophys Res Commun.
414
(3), 499-505 (2011).
74.
Nguyen QD, IbrahimMA, Watters A, et al. Ocular tolerability and efficacy of
intravitreal and subconjunctival injections of sirolimus in patients with non-infectious
uveitis: primary 6-month results of the SAVEStudy.
JOphthalmic Inflamm Infect.
3
(1),
32 (2013).
75.
Bowman ML, Hosseini K, Pham S, et al. Non-steroidal anti-inflammatory
ophthalmic compositions.WO2010102192 (2010)
76.
UrechDM. Functionalized polypeptides.WO2010006454 (2010)
77.
Ottiger M, Thiel MA, Feige U, et al. Efficient intraocular penetration of topical
anti-TNF-alpha single-chain antibody (ESBA105) to anterior and posterior segment
without penetration enhancer.
InvestOphthalmol Vis Sci.
50
(2), 779-86 (2009).
78.
Thiel MA, Wild A, Schmid MK, et al. Penetration of a topically administered
anti-tumor necrosis factor alpha antibody fragment into the anterior chamber of the
human eye.
Ophthalmology.
120
(7), 1403-8 (2013).
79.
Choi SM, SeoMJ, LeeYG, et al. Effects of DA-6034, a flavonoid derivative, on
mucin-like glycoprotein and ocular surface integrity in a rabbit model.
Arzneimittelforschung.
59
(10), 498-503 (2009).
80.
Seo MJ, Kim JM, Lee MJ, et al. The therapeutic effect of DA-6034 on ocular
inflammation via suppression of MMP-9 and inflammatory cytokines and activation of
theMAPK signaling pathway in an experimental dry eye model.
Curr Eye Res.
35
(2),
165-75 (2010).
81.
LanW, PetznickA, Heryati S, et al. Nuclear Factor-kappaB: central regulator in
ocular surface inflammation and diseases.
Ocul Surf.
10
(3), 137-48 (2012).
82.
Gjorstrup P. Compositions and methods for the treatment of ophthalmic
conditions. US2009011824 (2009)
83.
Therapeutics C. Developing therapies for critical unmet medical needs. RX
10045
-
Dry
Eye
and
Allergic
Conjunctivitis.
84.
Pharmaceuticals
R.
RX-10045
-
10045.asp2013
.
85.
Hong W, Yan S. Engineering Streptomyces tenebrarius to synthesize single
component of carbamoyl tobramycin.
Lett ApplMicrobiol.
55
(1), 33-9 (2012).
86.
Wang H, Pang B, Li Y, et al. Dexamethasone has variable effects on
mesenchymal stromal cells.
Cytotherapy.
14
(4), 423-30 (2012).
87.
Kabra B. Topical ophthalmic compositions containing tobramycin and
dexamethasone. US20107795316 (2010)
88.
WongB. JAK kinase inhibitors and their uses. US20060270694 (2006)
89.
Chang BY, Zhao F, He X, et al. JAK3 inhibition significantly attenuates
psoriasiform skin inflammation inCD18mutant PL/Jmice.
J Immunol.
183
(3), 2183-92
(2009).
